A carregar...
2SPD-010 Assessment of pertuzumab use for her2-positive breast cancer treatment
BACKGROUND: Pertuzumab is indicated for Her2-positive breast cancer (BC) in combination with trastuzumab and chemotherapy. PURPOSE: To describe pertuzumab utilisation as Her2-positive BC treatment at an oncology reference hospital and to analyse treatment-associated costs according to its different...
Na minha lista:
| Publicado no: | Eur J Hosp Pharm |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMJ Group
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7535369/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.31 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|